Provectus Chairman and CEO, Craig Dees, Ph.D, first hosts a luncheon on Oct. 29, starting at Noon at the Hyatt Regency (151 E. Wacker Drive) in Chicago, Ill. Dees will then present twice in New York City. The first will be at the Wall Street Analyst Forum, from Nov. 17-19 at the University Club, 1 W 54th St. He will then present at the 12th Annual New York Society of Security Analysts (NYSSA) Biotechnology/ Specialty Pharmaceutical Industry Conference, Dec. 2-3 (location TBA).
“As Provectus continues to make significant strides in developing our oncological and dermatological therapies, we continue to strive to increase investor awareness and visibility of the company,” Dees said.
Dees has spent more than 20 years in senior management positions at Provectus Pharmaceuticals, Inc.; Photogen Technologies, Inc.; the Oak Ridge National Laboratory; LipoGen, Inc.; and TechAmerica, Inc. Dees was a founder, senior scientist and founding director of Photogen before Provectus was formed. His responsibilities have included product design and development in the fields of ethical vaccines, cosmetics, human diagnostics and over-the-counter pharmaceuticals.
Provectus is a development-stage oncology and dermatology biopharmaceutical company. It has two drugs currently undergoing clinical trial; “PV-10″ as a therapy for metastatic melanoma and “PH-10″ as a topical treatment for psoriasis and atopic dermatitis. To complement drug development, the company has also originated a number of intellectual properties and technologies in the areas of imaging, medical devices and biotechnology.
In his presentations, Dees will discuss progress in PV-10. Interim reports of test subjects in its phase 2 clinical trial shows that PV-10 is well-tolerated with no unexpected side effects.
“In addition, long-term survival data for subjects participating in the phase 1 trial suggests that the response of treated lesions may be a good predictor of long-term outcome,” Dees said.
The company reports that In Phase 1, 40% of subjects achieved an objective response in their treated lesions by having them shrink or disappear, and 75% achieved loco-regional disease control where the lesions at least stopped growing.
About QualityStocks:
QualityStocks’ Small Cap Stock Newsletter is a free service that collects data from hundreds of Small-Cap online Investment Newsletters into one free Daily Newsletter Report.
Sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net
The Quality Stocks Daily Stock Report http://video.qualitystocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment